IVORAD - A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

niversity of Sydney0 个研究点目标入组 50 人开始时间: 2016年3月18日最近更新: 2021年9月27日

试验速览

阶段: 2 期
状态: 终止
发起方: niversity of Sydney
入组人数: 50

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomised controlled trial
主要目的: Treatment
盲法: Open (masking not used)

入排标准

年龄范围: 18 Years 至 o limit（—）
性别: All

入选标准

•1.Adult (18 years or over) with a histologically or cytologically confirmed diagnosis of NSCLC.
•2.At least one site of disease which is suitable for stereotactic radiotherapy, but for which radiotherapy is NOT URGENTLY REQUIRED at this time. The lesion is not required to be measurable or evaluable and must be nominated before randomisation. This lesion will be irradiated in patients randomised to receive radiation. The following criteria for the irradiated lesion must be met;
•Location must exclude the mediastinum and the central nervous system (vertebrae are allowed)
•Lesion size must be <=50mm and must not have been previously irradiated
•3.At least one lesion (target or non-target according to RECIST 1.1) that is separate and in addition to the lesion nominated for irradiation. This lesion cannot have been irradiated previously.
•4.Must have progressed after receiving 1 or 2 lines of chemotherapy for advanced disease including a platinum-based doublet. Maintenance chemotherapy following first line chemotherapy is considered a second line of chemotherapy. Relapse within 12 months of completing curative-intent platinum-based chemotherapy given either as adjuvant to surgery or as concurrent or sequential chemo-radiotherapy is considered one line of chemotherapy.
•5.ECOG performance status of 0 or 1 at the time of randomisation.
•6.Adequate bone marrow function (done within 14 days prior to randomisation and with values within the ranges specified below). Blood transfusions are permissible.
•White blood cell count >= 2 x 109/L
•Absolute neutrophil count >= 1.5 x 109/L
•Platelets >= 100 x 109/L
•Haemoglobin >= 90 g/L
•7.Adequate liver function (done within 14 days prior to randomisation and with values within the ranges specified below):
•Alanine transaminase <= 3 x upper limit of normal (ULN)
•Aspartate aminotransferase<= 3 x ULN
•Total bilirubin <= 1.5 x ULN (except patients with Gilbert Syndrome, who can have total bilirubin <= 5 x ULN)
•8.Adequate renal function (done within 14 days prior to randomisation and with values within the ranges specified below):
•Serum creatinine <=1.5 x ULN
•Creatinine clearance (CrCl) >=40 mL/min (use Cockcroft-Gault formula as per appendix 6)
•9.Tumour tissue (formalin-fixed paraffin embedded) should be available for PD-L1 testing and can be provided as a block or slides (archival tissue is acceptable). For patients without histological tumour tissue available, every attempt should be made to provide a cell block or unstained cytology slides. Patients will not be selected by PD-L1 status.
•10.Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments.
•11.Signed, written informed consent.

排除标准

•1.Active, known or suspected autoimmune disease. Patients are not excluded if they have vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to an autoimmune condition requiring only hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
•2.Any condition requiring systemic treatment with either regular corticosteroids (>10mg daily prednisone or equivalent dose of an alternative corticosteroid) or other immunosuppressive medications within 14 days of study drug administration. Intranasal, inhaled or topical steroids are permitted in the absence of active autoimmune disease.
•3.Patients with leptomeningeal or uncontrolled brain metastases are excluded. Controlled brain metastases are those which have been treated and are radiologically and/or clinically stable, and the patient is asymptomatic and does not require corticosteroids.
•4.Actionable mutation for which an approved, targeted therapeutic is available, e.g. known mutation of epidermal growth factor receptor (EGFR) or translocation of anaplastic lymphoma kinase.
•5.Chemotherapy in the last 4 weeks.
•6.Radiotherapy in the last 2 weeks.
•7.Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways.
•8.Current treatment with other investigational drugs or anti-cancer therapy.
•9.Life expectancy of less than 3 months.
•10.History of another malignancy within 3 years prior to randomisation. Patients with a past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or superficial transitional cell carcinoma of the bladder are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease free for at least 3 years after definitive primary treatment.
•11.Receipt of live attenuated vaccination within 30 days prior to registration.
•12.Positive test for hepatitis B virus surface antigen (HBVsAg) or antibodies to hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.
•13.History of other significant infection, including HIV. HIV testing not mandatory unless clinically indicated.
•14.Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.
•15.Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception to avoid pregnancy for 23 weeks after the last dose of nivolumab. Women of childbearing potential must have a negative pregnancy test done within 24 hours prior to randomisation. Men must have been surgically sterilised or use a (double if required) barrier method of contraception if they are sexually active with a woman of child bearing potential for a period of 31 weeks after the last dose of nivolumab.
•16. Recipients of a transplanted solid organ (kidney, liver, heart, lung) or of allogeneic bone marrow.

研究者

发起方

niversity of Sydney

相似试验

进行中（未招募）

1 期

A randomized, run-in, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapyMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-002986-36-ITFONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI184

进行中（未招募）

1 期

A randomized phase II study in which therapy is either switched to Nivolumab after 3 months of treatment or therapy is continued with a tyrosine kinase inhibitor in patients with metastatic renal cell carcinoma (RCC) and disease controladvanced or metastatic renal cell carcinoma (RCC)MedDRA version: 20.1Level: PTClassification code 10073251Term: Clear cell renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-002170-13-ATAIO-Studien-gGmbH244

进行中（未招募）

1 期

EUCTR2016-002170-13-DEAIO-Studien-gGmbH244

进行中（未招募）

1 期

A randomised phase II trial comparing two different ways of combining nivolumab and ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.Previously untreated metastatic clear cell renal cell carcinoma.MedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2017-001476-33-GBniversity of Leeds189

进行中（未招募）

1 期

Treatment of advanced lung cancerPatients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and patients with Small cell lung cancer (SCLC) after failure of platinum-based first-line therapy.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-003334-25-DEniversity of Cologne90